search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


HEBE III: A prospective, randomised, double blind, placebo controlled clinical study to examine the effects of a single bolus erythropoietin on left ventricular function in patients with an acute myocardial infarction.


- candidate number2094
- NTR NumberNTR678
- ISRCTNISRCTN46528154
- Date ISRCTN created26-mei-2006
- date ISRCTN requested22-mei-2006
- Date Registered NTR15-mei-2006
- Secondary IDsN/A 
- Public TitleHEBE III: A prospective, randomised, double blind, placebo controlled clinical study to examine the effects of a single bolus erythropoietin on left ventricular function in patients with an acute myocardial infarction.
- Scientific TitleHEBE III: A prospective, randomised, double blind, placebo controlled clinical study to examine the effects of a single bolus erythropoietin on left ventricular function in patients with an acute myocardial infarction.
- ACRONYMHEBE III
- hypothesisA single bolus EPO administered just before a primary PCI for a first acute myocardial infarction will increase left ventricular function after 4 months.
- Healt Condition(s) or Problem(s) studiedMyocardial infarction
- Inclusion criteriaSuccessful primary PCI (TIMI 2/3) for a first acute myocardial infarction, diagnosed by: 1. Chest pain suggestive for acute myocardial infarction; 2. Symptom onset < 12 hour after hospital admission, or < 24 hour in case ongoing ischemia; 3. ECG with ST-T segment elevation > 1 mV in 2 or more leads; 4. TIMI flow 0/1 before primary PCI on diagnostic coronary angiography.
- Exclusion criteria1. Hemoglobin levels > 10.6 mmol/L; 2. Anticipated additional revascularisation within 4 months; 3. Cardiogenic shock; 4. Presence of other serious medical conditions; 5. Pregnancy/breast feeding; 6. Malignant hypertension; 7. End stage renal failure (kreatinin > 220 micromol/l); 8. Previous treatment with rh-EPO; 9. Blood transfusion <12 weeks prior to randomisation; 10. Allergy against rh-EPO; 11. Polycytemia verae; 12. Previous acute myocardial infarction; 13. Concomitant inflammatory or malignant disease; 14. Recent trauma or major surgery; 15. Unwilling to sign informed consent; 16. Contra-indications for MRI (pacemaker and other metal subjects).
- mec approval receivedno
- multicenter trialyes
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type-
- Studytypeintervention
- planned startdate 1-sep-2006
- planned closingdate1-sep-2008
- Target number of participants400
- Interventions1. One bolus of EPO (Eprex, about 60.000 IU) will be administered intravenously in 30 minutes, within 3 hours after the primary PCI procedure. OR 2. Placebo
- Primary outcomeThe main study endpoint will be left ventricular ejection faction, measured with Cardiac Magnetic Resonance Imaging at 4 months after onset of the acute myocardial infarction.
- Secondary outcomeSecondary study endpoints are: 1. Myocardial infarct size, summarised as the percentage of left ventricular mass, measured with Cardiac Magnetic Resonance Imaging at 4 months after onset of the acute myocardial infarction; 2. Cardiovascular events (cardiovascular death, re-myocardial infarction, re-PCI or CABG, stroke, heart failure) from the onset of the acute myocardial infarction to 4 months afterwards; 3. Enzymatic infarct size with computerised measurements of CK and CK-MB; 4. Safety endpoint: Incidence of death, stroke, onset or worsening of CHF, deep vein thrombosis, malignant hypertension (RR>250/125), re-myocardial infarction, pulmonary embolism, seizure.
- Timepoints
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESMSc J. Hogenhuis
- CONTACT for SCIENTIFIC QUERIESMD. PhD A.A. Voors
- Sponsor/Initiator University Medical Center Groningen (UMCG), Trial Coordination Center, Interuniversity Cardiology Institute of the Netherlands (ICIN)
- Funding
(Source(s) of Monetary or Material Support)
Interuniversity Institute of Cardiology (ICIN), The Netherlands, University Medical Center Groningen (UMCG)
- PublicationsN/A
- Brief summaryErythropoetin (EPO) is commonly known as an effective treatment for anemia, (partly) caused by an inadequate production of endogenous EPO (e.g., renal failure). However, we and others suggested several important extra-hematopoeitic effects of EPO, which might be beneficial in the setting of an acute myocardial infarction. Recent animal studies provided very consistent evidence for a reduced infarct size and improved left ventricular function caused by EPO administration. In addition, we and others have mainly explained the beneficial effects of EPO by non-hematopoietic effects, such as reduction of apoptosis and stimulation of neovascularisation. Clinical studies with EPO in non-anemic patients are scarce. However, in our safety study, EPO administration in patients with an acute myocardial infarction was safe and well tolerated. Therefore the primary objective of this study is to establish the effects of a single bolus EPO administered just before a primary PCI for a first acute myocardial infarction, on left ventricular function after 4 months.
- Main changes (audit trail)
- RECORD15-mei-2006 - 29-mei-2006


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl